A preliminary investigation of the safety and effectiveness of oral probiotics supplementation for reducing the risk of kidney stone in adults with recurrent kidney stone colic or acute episode of colicky pain: An open-label, single-arm, prospective, interventional, proof-of-science study. - Nil

Meteoric Biopharmaceuticals Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•1.The subject is an adult aged between 18 to 55 years old.
•2.The subject has a history of recurrent kidney stone colic or acute episode of colicky pain on clinical examination by Physician.
•3.The subject is willing to provide written informed consent and comply with study procedures, including overnight stay for 24 hours at the study centre during both visits.
•4.The subject is willing to abide by the study protocol and restrictions, including abstaining from using any other oral or topical treatments for kidney stone colic during the study period.
•5.The subject is in a stable medical condition, not requiring immediate intervention or hospitalization.
•6.If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation.
•a.Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device/injection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence).
•b.Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration.

•1 Subject has a history of severe renal impairment or chronic kidney disease.
•2 Subject is pregnant/lactating, or is planning on become pregnant during the course of the study.
•3 Subject has presence of significant medical or psychiatric conditions that may interfere with study participation or interpretation of results.
•4 Subject has a history of substance abuse or dependence.
•5 Subject has severe systemic complications of viral infections, cardiovascular disorders, neurological disorders, renal disorders, or autoimmune disorders.
•6 Subject has participated in clinical studies or received any investigational agent in the previous 30 days.
•7 Subject has any condition that, in the judgement of investigator, would compromise the safety of subject or study integrity.

发起方

Meteoric Biopharmaceuticals Pvt. Ltd.